Journey Medical to acquire hyperhidrosis treatment Qbrexza

Journey Medical will acquire Qbrexza from Dermira, according to a press release.

Qbrexza (glycopyrronium), an FDA-approved cloth towelette used as a topical treatment for primary axillary hyperhidrosis in adults and adolescents, generated $24 million in U.S. net sales in 2020, the release said.

Journey Medical, a partner company of Fortress Biotech, and Dermira, a wholly owned subsidiary of Eli Lilly and Company, will complete the transaction in the second quarter.

“We are thrilled to expand our footprint in dermatology with the addition of Qbrexza to our growing portfolio of prescription dermatology brands,” Claude Maraoui, Journey Medical president and CEO, said in the release. “Acquiring Qbrexza will allow us to provide an accessible and convenient product to the millions of Americans who seek relief from excessive underarm sweating, many of whom remain undiagnosed and untreated.”